-+ 0.00%
-+ 0.00%
-+ 0.00%

EyeGene Seeks Approval to Amend Phase 2/3 Trial of Meningococcal Vaccine EG-MCV4

PUBT·11/10/2026 10:06:59
Listen to the news
EyeGene Seeks Approval to Amend Phase 2/3 Trial of Meningococcal Vaccine EG-MCV4
  • EyeGene applied on Nov. 10, 2026, for South Korean regulatory clearance to amend its Phase 2/3 trial of meningococcal vaccine EG-MCV4.
  • The regulator requested double-blind trial wording and additional control participants to maintain blinding in the Phase 3 safety cohort.
  • Target enrollment is 125 participants in Phase 2 and 998 in Phase 3, including 268 in the safety-only cohort.
  • The trial will assess immune responses and safety, with Phase 3 testing whether EG-MCV4 performs no worse than GSK’s Menveo.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EyeGene Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261110900805), on November 10, 2026, and is solely responsible for the information contained therein.